Imagine you or a loved one has just had a stroke. In the frantic rush to the hospital, a doctor has to choose which clot-busting drug to give. That single choice could shape your ability to walk, talk, and live independently three months later. A massive review of 21 clinical trials, involving over 16,800 patients, compared all the available drugs given within 4.5 hours of a stroke. The goal was to see which ones help people recover best and which are safest. The findings are striking. Two newer drugs stood out for helping more people achieve an excellent recovery—meaning they could walk and care for themselves with no help. One, called reteplase (given as two 18 mg doses), was better than the standard drug alteplase at helping patients get back to normal. Another, a new version of staphylokinase, showed an even stronger benefit for excellent recovery. On safety, this new staphylokinase also appeared to carry a lower risk of a dangerous brain bleed than one dose of another newer drug, tenecteplase. Importantly, none of the drugs showed a difference in the risk of dying within 90 days. The bottom line is clear: in the race against time after a stroke, the specific medication used is a critical factor for a good outcome.
Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again.
Plain Language Summary
What this means for you:
For stroke patients, two newer clot-busting drugs were linked to better recovery odds than the current standard. What this means for you:
For stroke patients, two newer clot-busting drugs were linked to better recovery odds than the current standard. View Original Abstract ↓
BackgroundAlthough several newer thrombolytic agents for acute ischemic stroke (AIS) within 4.5 h of onset have been developed, their relative efficacy, safety, and optimal dosing remain unclear. A comprehensive comparison across all available agents is therefore needed.MethodsWe systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for English-language reports of randomized controlled trials (RCTs) published up to December 12, 2025. Eligible trials enrolled adult AIS patients treated with intravenous thrombolysis. Primary outcomes were 90-day excellent (modified Rankin Scale [mRS] score 0–1) and good (mRS 0–2) functional outcomes. Safety outcomes were symptomatic intracranial hemorrhage (sICH), and all-cause mortality. A frequentist network meta-analysis using a fixed-effect consistency model was conducted to estimate odds ratios (ORs) with 95% confidence intervals (CIs).ResultsA total of 21 RCTs involving 16,837 patients were included. For achieving mRS 0–1, reteplase (18 + 18 mg) showed a statistically significant advantage over alteplase (0.9 mg/kg) (OR 1.60; 95% CI, 1.27–2.02), and non-immunogenic recombinant staphylokinase (10 mg) demonstrated a statistically significant benefit (OR 2.23; 95% CI, 1.43–3.48). Reteplase (18 + 18 mg) also improved the likelihood of mRS 0–2 compared with alteplase (OR 1.41; 95% CI, 1.08–1.84). For safety, non-immunogenic recombinant staphylokinase significantly reduced sICH risk compared with tenecteplase 0.25 mg/kg (OR 0.31; 95% CI, 0.11–0.94). No significant differences in 90-day mortality were observed among treatments.ConclusionWithin the 4.5-h treatment window, reteplase (18 + 18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associated with the highest probabilities of improved functional outcomes.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251152754.